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Abstract 
Colonoscopy is a relatively scarce resource in many countries, including Scotland, 
and a simple investigation which would aid general practitioners in particular in 
decision-making as to which patients presenting with lower bowel symptoms 
warranted referral would be of much help. Faecal immunochemical tests for 
haemoglobin (FIT) have many advantageous characteristics and are now proven to 
be of considerable value in the timely assessment of patients with symptoms of 
lower bowel disease. Quantitative FIT provide numerical estimates of faecal 
haemoglobin concentration (f-Hb) and, at low f-Hb cut-off, FIT have high sensitivity 
for colorectal cancer (CRC) and could be used as a rule-in test to stimulate rapid 
referral, especially when symptoms are suggestive of serious bowel disease. 
Perhaps more importantly, a low f-Hb gives considerable reassurance that significant 
bowel disease (CRC + higher-risk adenoma + inflammatory bowel disease) is absent 
and further investigation may not be warranted: however, no test is perfect, so some 
cases will remain undetected using FIT alone and robust safety netting is required, 
possibly including watching and waiting, referral to clinics in secondary care, or a 
repeat FIT. Moreover, the FIT results should not be taken in isolation, but clinical 
impressions and the results of other investigations, probably including the full blood 
count, should be considered. Challenges still exist, however, and harmonisation of 
aspects of the available FIT analytical systems is required.  Moreover, a number of 
seemingly valid clinical concerns remain and these require resolution through further 
research and reporting of studies done in real clinical practice. 
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Introduction 
Colonoscopy is crucial to the early diagnosis of significant bowel disease (SBD), 
including colorectal cancer (CRC) and inflammatory bowel disease (IBD). 
Unfortunately, there is evidence, such as that gathered by Bowel Cancer UK, 
demonstrating that there is a current crisis in endoscopy throughout the UK with 
services being underfunded, demand outstripping supply, chronic staff shortages 
and growing waiting lists for investigations.1  In part, the demand which has led to 
the increase in referrals from primary care to endoscopy, gastroenterology and 
surgery in secondary care has been due to the publicity surrounding the bowel 
screening programmes running in the four countries of the UK and the information 
that is given to participants with negative screening test results on the need to pay 
attention to any bowel symptoms and report these as soon as they become 
apparent. Moreover, campaigns such as Detect Cancer Early in Scotland2 and Be 
Clear on Cancer in England3 have encouraged people with symptoms to make an 
appointment with their general practitioner (GP) as soon as possible.   
Unfortunately, although the symptoms of SBD, namely, repeated rectal bleeding or 
blood evident on passed faeces, a change in bowel habit that continues for more 
than four weeks without returning to usual, diarrhoea on its own or with constipation, 
abdominal pain especially after eating, unexplained loss of weight and tiredness, are 
very common presentations in primary care; however, these are well documented to 
be very poor predictors of SBD.4  Thus, the challenge was to find and then use an 
investigation that assists the GP to determine which patients with lower bowel 
symptoms would benefit most from referral to secondary care for colonoscopy. The 
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primary purpose of this review is to summarise the evidence that faecal 
immunochemical tests for haemoglobin (FIT) can assist in the triage of these 
patients and to discuss the challenges that still exist to ubiquitous introduction of FIT 
as a routine investigation in primary care. 
Faecal immunochemical tests for haemoglobin (FIT) 
Faecal immunochemical tests for haemoglobin (FIT) make use of antibodies, usually 
polyclonal, to the globin moiety of haemoglobin. Most FIT have simple to use, 
hygienic faecal specimen collection devices in which a probe attached to the cap of 
the device is used to collect faeces into dimples or grooves at the end of the probe. 
Then, the probe is reinserted into the device, which contains a volume of buffer, 
which confers some stability on any haemoglobin (Hb) present in the faeces. An 
important point is that these must be used for collection of faecal samples for FIT 
analysis since faecal haemoglobin (f-Hb) is unstable; collection of faeces into the 
traditional pot with later analysis can lead to false negative test results.5 FIT have 
many positive attributes, including being unaffected by dietary constituents and more 
specific for lower gastrointestinal bleeding. 
FIT are available in two formats.6 The first is qualitative FIT, which give a 
dichotomous, positive/negative result, usually using lateral-flow 
immunochromatographic cassettes or strips, similar to the very widely used 
pregnancy tests which detect urinary human chorionic gonadotropin (hCG).6 The 
disadvantages of qualitative FIT have been very well documented7,8 and, since these 
are not used widely in the UK,9 this review is mainly concerned with the application 
of quantitative FIT.  Quantitative FIT, usually involving automated 
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immunoturbidimetry on small bench-top dedicated analytical systems, provide a 
numerical estimate of the faecal haemoglobin concentration (f-Hb).6  
Faecal haemoglobin concentrations (f-Hb) 
Quantitative FIT have become the most widely used non-invasive investigation in 
both opportunistic and programmatic screening for CRC10 and much has been 
learned from the results obtained in screening about f-Hb and the factors that affect 
f-Hb.11    
It has been shown that f-Hb is directly related to the severity of colorectal disease.12 
In addition, it has been documented in more detail13 that median f-Hb is higher in 
those with CRC than those with no pathology or with minor non-neoplastic 
pathology. Individuals with low-risk adenoma (LRA), and polyp CRC cancers have 
lower f-Hb than more advanced stage CRC. Higher f-Hb is also found in those with 
higher risk adenoma (HRA: three or more polyps, any polyp >10 mm diameter) than 
with LRA, in large compared with small adenoma, and also in adenoma displaying 
high-grade dysplasia as compared to those with low-grade dysplasia. Thus, it is 
hardly surprising that screening the asymptomatic using FIT is very successful.  
In addition, in CRC screening programmes, because of this relationship, as the f-Hb 
cut-off concentration applied to decide which participants are offered colonoscopy is 
increased, the positivity rate, CRC and adenoma detection rates, and sensitivity 
decrease, while positive predictive value and specificity increase.14 Further, as the f-
Hb cut-off is increased, the interval cancer proportion, that is the number of CRC 
found in participants who had a negative screening test result but had a diagnosis of 
CRC before the next screening episode was scheduled, rises.15  
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Furthermore, a number of factors affect the f-Hb found in different populations: f-Hb 
is higher in men than in women and increases with age16,17 and these relationships 
differ in magnitude from country to country.18 In addition, f-Hb is dependent on 
deprivation, f-Hb increasing as deprivation increases.17,19  In consequence, there is 
much current interest in using more complex interpretation of the f-Hb of participants 
in CRC screening than application of one f-Hb cut-off for all to decide on referral for 
colonoscopy through incorporation of such variables into a risk-score.20 In addition, it 
has been elegantly shown that f-Hb below the cut-off applied in CRC screening is 
related to the risk of future colorectal disease, particularly if detectable on two 
occasions.21 
FIT in the assessment of patients presenting with lower bowel symptoms: 
background 
Even until recently, in spite of the proven relationship between f-Hb and severity of 
colorectal disease and the successful use of FIT in CRC screening, there was little 
interest in the application of FIT in the assessment of patients presenting in primary 
care with lower bowel symptoms.  This may have been in part due to the fact that the 
traditional tests for the presence of blood in faeces, namely, guaiac-based faecal 
occult blood tests (gFOBT), had many problems and difficulties in all stages of the 
performance of this apparently simple investigation.22 Moreover, older guidelines 
from the National Institute for Health and Care Excellence (NICE),23 the Scottish 
Intercollegiate Network (SIGN)24 and the British Society of Gastroenterology25 all 
stated that gFOBT lacked the clinical characteristics required for the detection of 
CRC and for the investigation of iron deficiency anaemia. Because of both of these 
deficiencies, many medical laboratories eliminated gFOBT from their repertoires and 
6
 
 
encouraged cessation in all clinical settings such as wards, clinics, surgical 
admission units and accident and emergency departments. 
However, in 2015, the situation changed. NICE issued a revision of Clinical 
Guideline 27 - Referral guidelines for suspected cancer - published in 200523 as 
NICE Guideline NG12 - Suspected cancer: recognition and referral.26 The guideline 
concerning lower gastrointestinal cancer stated: 1.3.1. Refer adults using a { 
HYPERLINK "https://www.nice.org.uk/guidance/ng12/chapter/terms-used-in-this-guideline" } (for 
an appointment within two weeks) for CRC if: they are aged 40 and over with { 
HYPERLINK "https://www.nice.org.uk/guidance/ng12/chapter/terms-used-in-this-guideline" 
} weight loss and abdominal pain or they are aged 50 and over with unexplained 
rectal bleeding or they are aged 60 and over with: iron-deficiency anaemia or 
changes in their bowel habit, or tests show occult blood in their faeces (see Section 
1.3.4).  Section 1.3.4 followed to detail: Offer testing for occult blood in faeces to 
assess for CRC in adults without rectal bleeding who: are aged 50 and over with 
unexplained abdominal pain or weight loss, or are aged under 60 with changes in 
their bowel habit or iron-deficiency anaemia, or are aged 60 and over and have 
anaemia even in the absence of iron deficiency.  
It is worthy of note that the guidance in Scotland is far less prescriptive. The Scottish 
referral guidelines for suspected cancer document that high-risk features which 
warrant urgent suspicion of cancer referral are: repeated rectal bleeding without an 
obvious anal cause or any blood mixed with the stool, persistent change in bowel 
habit especially to looser stools (more than 4 weeks), a right-sided abdominal mass 
or palpable rectal mass, unexplained iron deficiency anaemia and a past history of 
lower gastrointestinal cancer with any of the symptoms above.27 The most recent 
version of SIGN: Diagnosis and management of CRC. A national clinical guideline. 
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2011, after revision in 2016, does contain some material on the use of FIT in 
asymptomatic population screening.24 However, key point iii still states: 
Investigations: No examinations or investigations other than abdominal and rectal 
examination and full blood count are recommended. Faecal occult blood testing is 
not indicated and should not influence decision making in symptomatic patients. 
Thus, the guidelines in England and Scotland are different. 
 
When NICE NG12 was issued, there was considerable negativity expressed. For 
example, Steele et al stated, inter alia, that the guidance was particularly worrying for 
people under 60 years with iron deficiency anaemia, that gFOBT should be used 
only in laboratories with dedicated staff and strict quality assurance and for 
population screening, and that anyone seeking advice about symptoms wishes 
reassurance that there is no serious disease but gFOBT is not sufficiently sensitive 
for this purpose and, because negative tests provide reassurance, diagnosis is likely 
to be delayed.28  In response, Hamilton et al responded that half of patients with 
CRC did not meet the criteria for urgent referral under the previous guidance (CG27) 
and these patients, who were at low risk but did not have no risk symptoms, did 
badly, with longer times to diagnosis, more emergency admissions and higher 
mortality. NG12 sought to improve this and the specific guideline was based on six 
research papers on faecal occult blood testing (FOBT) in the symptomatic primary 
care population. Overall, these supported the use of FOBT. However, the response 
did state that FIT may prove superior to gFOBT when more studies were performed 
and NG12 deliberately did not actually detail which faecal test should be used.29 
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Similar caveats regarding gFOBT were expressed in the literature of laboratory 
medicine, it being stated that NG12 was ill-judged and the advice to those 
responsible for routine clinical biochemistry laboratories was to resist calls to 
introduce or re-instate gFOBT. However, this editorial did state that, in the future, 
laboratories might wish to consider offering FIT for the groups detailed in NG12.30 
The rationale available at that time supporting the use of FIT in this clinical context 
was clearly documented in an editorial published simultaneously, which  suggested 
that professionals in laboratory medicine should take up the challenges of 
introducing FIT in the assessment of patients presenting in primary care with lower 
bowel symptoms and work with others in progressing the existing evidence base on 
this use of f-Hb in assessment of the symptomatic.31 
 
In view of the controversy surrounding the recommendations in NG12 to use tests for 
faecal occult blood and the wide disapproval of the use of gFOBT, NICE set up a 
Diagnostic Advisory Committee with the remit of investigating the evidence for the 
use of quantitative faecal immunochemical tests to assess symptomatic people who 
are at low risk of CRC in primary care. The final Diagnostics Guidance DG30 on 
quantitative faecal immunochemical tests to guide referral for CRC in primary care 
was issued in 2017.32  The major recommendations were that three commercially 
available quantitative faecal immunochemical test analytical systems were 
recommended for adoption in primary care to guide referral for suspected CRC in 
people without rectal bleeding who have unexplained symptoms but do not meet the 
criteria for a suspected cancer pathway referral outlined in the NICE guideline on 
suspected cancer, NG12,24 and results should be reported using a threshold of 10 
micrograms of haemoglobin per gram of faeces (µg Hb/g faeces). Since the issue of 
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these guidelines, NG12 has been updated and, in July 2017, the detailed 
recommendation on use of tests for occult blood in faces (1.3.4 detailed above) was 
stood down and 1.3.4 became: This recommendation has been replaced by our 
diagnostics guidance on quantitative faecal immunochemical tests to guide referral 
for CRC in primary care (DG 30).32 The diagnostics guidance recommends tests for 
occult blood in faeces, for people without rectal bleeding but with unexplained 
symptoms that do not meet the criteria for a suspected cancer pathway referral in 
recommendations 1.3.1 to 1.3.3. In essence, this tells that it is recommended that 
GP request a FIT on any patient that is causing concern. The evidence supporting 
the DG30 recommendations follows in the next section of this review. 
 
FIT in the assessment of patients presenting with lower bowel symptoms: the 
evidence 
 
During and following the generation of NICE NG12 in 2015, a number of peer-
reviewed publications were published concerning the use of FIT in assessment of 
patients presenting with lower bowel symptoms. These have been described in detail 
in two open-access systematic reviews33,34 and in a very recent chapter, which does 
not only consider quantitative FIT but also details studies using qualitative FIT and 
also other biomarkers which potentially could supplement clinical data and the 
results of FIT analysis, including calprotectin and M2-PK, the dimeric form of 
pyruvate kinase isoenzyme type M2.35   In consequence, the fine details of these 
studies36-42 will not be documented here. Since the most recent publication,35  there 
have only been two further publication concerning the use of quantitative FIT in the 
assessment of patients with symptoms. One concerns an analytical and clinical 
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evaluation of a recently available FIT analytical system (SENTiFIT 270, Sentinel 
Diagnostics, Milan, Italy).43 Clinical sensitivity for advanced colorectal neoplasia 
(ACRN: CRC + AN) at f-Hb cut-offs from 10 to 60 μg Hb/g faeces ranged from 28.9% 
to 46.5% and specificity ranged from 85% to 93.2% (95% CI, 91.2%-94.8%): the 
positive predictive values (PPV) for detecting CRC and AA ranged from 11.6% to 
20.6% and 34.7% to 42.3%, respectively, and the negative predictive values (NPV) 
ranged from 90.2% to 88.4%.  It was concluded that this FIT provided a specific and 
accurate test for detecting ACRN in symptomatic patients and those undergoing 
surveillance. Unsurprisingly, using two faecal samples per patient increased clinical 
sensitivity with a slight decrease in specificity. The second recent publication44 
compared the utility of f-Hb as the initial investigation with the NICE NG12 symptom-
based guidelines using data from three studies done in Scotland.36-38 The sensitivity 
and NPV of f-Hb for SBD were 63.2% and 96.0%, respectively. It was concluded that 
f-Hb provides a good rule-out test for SCD and has significantly higher overall 
diagnostic accuracy than NG12 
 
Taken with the other studies using quantitative FIT, exactly as listed in detail 
previously in the chapter in Timely Diagnosis of Colorectal Cancer,35 the results 
provide evidence that demonstrate the following: 
• in patients with lower bowel symptoms, f-Hb is higher in those with CRC than 
in those with advanced adenoma (AA: similar to HRA) and IBD, and f-Hb in 
these two groups is higher than in those with less significant bowel disease 
such as non-advanced adenoma (NAA: similar to LRA), haemorrhoids and 
simple diverticular disease, and those with no abnormalities found on 
colonoscopy, 
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• high f-Hb is not only found in patients with SBD, but also in some who have 
less significant pathology and no abnormality, and so the PPV is not optimal, 
 
• the higher the f-Hb cut-off used for referral for colonoscopy, the lower are the 
sensitivity, positivity rate and NPV, and the higher the specificity and PPV, 
 
• f-Hb cut-off at the limit of quantitation (LoQ) documented by the 
manufacturers of the FIT analytical system used should be applied to give 
highest sensitivity for detection of SBD and highest NPV, albeit at the 
expense of specificity and PPV, 
 
• at such f-Hb cut-offs, some CRC and some AA and IBD will be missed and 
safety-netting is mandatory, 
 
• f-Hb provides a good rule-in test for CRC and a patient with a f-Hb above the 
LoQ should be referred for urgent colonoscopy, 
 
• f-Hb provides a good rule-out test for SBD: a result below the f-Hb cut-off 
means that SBD is unlikely and many patients can be reassured regarding the 
absence of disease and not referred immediately, or at all, for colonoscopy,  
 
• f-Hb is better at detection of CRC than some guidelines based upon 
symptoms, age and other factors for referral from primary care when CRC is 
suspected, 
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• one sample is sufficient for detection or exclusion of most SBD, 
 
• men and women with symptoms have different clinical outcomes at a single f-
Hb cut-off, 
 
• using two samples from each patient shows that there may be considerable 
within-subject variation of f-Hb from day to day and this is worthy of further 
research as has been recently done for faecal calprotectin45 and 
 
• ubiquitous use of f-Hb as the initial investigation in primary care could 
undoubtedly help direct colonoscopy resources to those who would benefit 
most. 
 
Thus, the evidence is that the recommendations of NICE DG30 are cogent and 
application of quantitative FIT in assessment of symptomatic patients would seem to 
well fulfil the challenge to find and then use an investigation that assists the GP to 
determine which patients with lower bowel symptoms would benefit most from 
referral to secondary care for colonoscopy. That this indeed remains a current 
requirement is evidenced for the findings in the recent major national audit on cancer 
diagnosis in primary care in England.46   The audit provided a detailed picture of the 
timeliness of cancer diagnosis in patients who presented with symptoms. For colon 
and rectal cancers, the average time it took from first reporting symptoms to a cancer 
diagnosis was 49 and 42 days respectively. Around 25-30% of patients with colon 
and rectal cancer waited more than 90 days for a cancer diagnosis. Furthermore, 
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approximately 30% of patients diagnosed with bowel cancer experienced avoidable 
delays to their diagnosis. 
 
FIT in the assessment of patients presenting with lower bowel symptoms: 
challenges 
 
Although the evidence is that FIT provide a good test to rule-in CRC and a good test 
to exclude SBD, there are still a number of challenges. 
 
NICE NG12 suggests that a single f-Hb cut-off of 10 µg Hb/g faeces be used in 
assessment of patients presenting with symptoms, irrespective of their sex or age, 
factors well known to affect f-Hb. The publications on FIT36-43 have receiver operating 
characteristic (ROC) curves and/or tables of clinical performance characteristics at 
various f-Hb cut-offs: these suggest that 10 µg Hb/g faeces is the most appropriate f-
Hb cut-off. Further, the analytical performance characteristics of the available FIT 
analytical systems are such that a f-Hb cut-off of 10 µg Hb/g faeces is apposite.  This 
approximates to the LoQ of the most used FIT analytical systems. Laboratories 
providing FIT for triage of the symptomatic must use the LoQ as the lowest limit to 
give a numerical result and this is 10 µg Hb/g faeces for the OC-Sensor (Eiken 
Chemical Co., Ltd, Tokyo, Japan) and 7 µg Hb/g faeces for the HM-JACKarc 
(Kyowa-Medex, Co., Ltd, Tokyo, Japan): concentrations less than this are very 
interesting from an academic point of view but cannot be simply reported.11,47 LoQ is 
the lowest  concentration at which performance that meets analytical performance 
specifications is achieved. This is not the same as the limit of detection (LoD), the 
lowest concentration that is statistically different from a blank (sample with no 
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haemoglobin present), and the f-Hb above which data can be documented for 
research and development purposes.11,47  It is noteworthy that NICE DG30 
documents that: companies should provide advice about the performance 
characteristics of the assays to laboratories, and ensure standardisation of results.32  
This is stated because there is considerable evidence that FIT analytical systems do 
not give identical results on the same faecal samples,48 probably due to the fact that 
polyclonal antibodies to the epitopes on the globin moiety of haemoglobin are used 
and they react differently to the heterogeneous mix of native haemoglobin and its 
degradation products present in faeces: this could affect the number of positive and 
negative results if a single f-Hb cut-off was used. Moreover, faeces is a 
heterogeneous matrix even in one bowel movement and there is some concern 
regarding the small specimen collected being representative. There are other 
analytical challenges and these are currently being addressed by the recently formed 
Working Group on FIT of the Scientific Division of the International Federation of 
Clinical Chemistry and Laboratory Medicine.49 It is also important to note that 
manufacturers of FIT do improve their systems over time, an example being the 
reformulation of the buffers in the specimen collection devices so as to enhance 
haemoglobin stability:50  in consequence, data from older studies using outdated FIT 
analytical systems or components may not be applicable to those from for newer 
systems.  
 
More important, perhaps, are the clinical concerns. The first is that the 
recommendations on the use of FIT in NICE NG12 26 and DG30 32 applies only to 
patients with low risk symptoms. The evidence for this simply does not exist, since 
the studies done to date,36-42 apart from that of Mowat et al38 which was performed in 
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primary care, were concerned with patients who had already been referred to 
secondary care and were not only concerned with patients with low risk symptoms. 
Further work on this interesting group is required as soon as possible.  In reality, it is 
highly likely that GP will request a FIT on all patients presenting with lower bowel 
symptoms and this can be justified on the grounds that symptoms in SBD and other 
bowel disorders overlap considerably. However, it might be considered that there 
may be good grounds for fast-tracking those with the symptoms and signs as 
documented requiring urgent referral in current NICE NG1226 and HIS27 guidance, 
irrespective of the FIT result: again this is a facet of the use of FIT in assessment of 
the symptomatic which requires objective investigation. 
 
The second problem is that, to date, there are no peer-reviewed publications on the 
application of FIT in real practice. NICE recommend that commissioning groups 
adopting the endorsed FIT analytical systems should audit their outcomes and 
monitor the associated resource use.32 Again, it would be of real interest to see  
such audits of outcomes performed and the results promulgated to all healthcare 
professionals involved in the use of FIT and to have lessons learned in the 
implementation of FIT also well documented and disseminated. Further, it has been 
stated that use of FIT by GP might actually increase the number of referrals for 
colonoscopy since they will request this investigation on every patient presenting 
with lower bowel symptoms and, since the PPV is low, many with false positive FIT 
results will be referred to secondary care: again, research into the results attained in 
real practice is required. 
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Thirdly, the recommendation in NICE DG30 was that the f-Hb cut-off of 10 µg Hb/g 
faeces should be applied ubiquitously, although it was considered that further 
research was needed to determine whether f-Hb are influenced by age, sex and 
medicines that increase the risk of gastrointestinal bleeding.32 It was noted that such 
data could be used to further develop risk scores which include variables such as 
age, sex and symptoms to help determine pre-test probability. Such risk scoring 
approaches do exist and have been recently reviewed.51  Only a few of the models 
suggested incorporate f-Hb, examples being the COLONPREDICT approach52 and 
the FAST Score developed with much input from research centres in Scotland:53 
their application in routine clinical care has not yet been established. 
Fourthly, it must be realised that no test in laboratory medicine is perfect. Using the f-
Hb cut-off of 10 µg Hb/g faeces a few cases of CRC will be missed and rather more 
cases of HRA and IBD.    Thus, there is a real need for robust safety netting as 
described above, which would not only include watching and waiting but might also 
involve referral to gastroenterology or surgery clinical in secondary care or 
undertaking a repeat FIT.  Moreover, it is vital to note that the FIT results should not 
be viewed in isolation but clinical judgement on the individual patient and the results 
of physical examinations and the full blood count should be taken into account. 
 
Conclusions 
 
FIT are now proven to be very useful in the timely assessment of patients with 
symptoms of lower bowel disease. In particular, FIT can guide in the decision-
making as to which patients presenting in primary care with lower bowel symptoms 
would most benefit from referral for colonoscopy. Quantitative FIT provide numerical 
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estimates of f-Hb and, at low f-Hb cut-off, FIT have high sensitivity for colorectal 
cancer (CRC) and could be used as a rule-in test and stimulate rapid referral, 
especially when symptoms are suggestive of serious bowel disease. Perhaps more 
importantly, low f-Hb provides considerable reassurance that significant bowel 
disease is absent and further investigation may not be required: however, no test is 
perfect so some cases will remain undetected and robust safety netting is required, 
including, for example, watching and waiting, referral to appropriate clinics in 
secondary care, or a repeat FIT. In addition, the FIT results should not be taken in 
isolation but clinical impressions and the results of other investigations, probably 
including the full blood count, should be considered. Challenges still exist, however, 
and harmonisation of aspects of the available FIT analytical system is required.  
Moreover, a number of valid clinical concerns remain and these require resolution. 
Thus, although there is considerable positive evidence regarding the use of FIT in 
assessment of patients presenting in primary care with lower bowel symptoms, there 
is still much of importance to learn about the application in everyday clinical practice 
which can only be ascertained when this test is introduced and the results in this 
setting are generated and subsequently widely disseminated.  
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